Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | insulysin unit 3 (M16 family) | 0.0051 | 0.9784 | 0.9784 |
Loa Loa (eye worm) | insulin-degrading enzyme | 0.0051 | 1 | 0.5 |
Schistosoma mansoni | insulysin (M16 family) | 0.0029 | 0.2821 | 0.2821 |
Toxoplasma gondii | insulysin, putative | 0.0048 | 0.8989 | 0.8989 |
Trypanosoma brucei | peptidase, putative | 0.0051 | 1 | 0.5 |
Schistosoma mansoni | nardilysin (M16 family) | 0.0051 | 1 | 1 |
Toxoplasma gondii | rhoptry metalloprotease toxolysin TLN1 | 0.0051 | 1 | 1 |
Toxoplasma gondii | toxolysin TLN4 | 0.0023 | 0.1011 | 0.1011 |
Echinococcus multilocularis | nardilysin | 0.0051 | 1 | 1 |
Toxoplasma gondii | sporozoite developmental protein | 0.0051 | 1 | 1 |
Trypanosoma cruzi | peptidase, putative | 0.0051 | 1 | 0.5 |
Schistosoma mansoni | insulysin unit 3 (M16 family) | 0.0051 | 0.9784 | 0.9784 |
Toxoplasma gondii | peptidase M16 inactive domain-containing protein | 0.0031 | 0.3615 | 0.3615 |
Schistosoma mansoni | nardilysin (M16 family) | 0.0051 | 1 | 1 |
Chlamydia trachomatis | insulinase family protease III | 0.0051 | 1 | 0.5 |
Leishmania major | phosphoglycan beta 1,3 galactosyltransferase 5 | 0.0051 | 1 | 0.5 |
Echinococcus granulosus | insulin degrading enzyme | 0.0051 | 1 | 1 |
Echinococcus multilocularis | insulin degrading enzyme | 0.0051 | 1 | 1 |
Echinococcus granulosus | nardilysin | 0.0051 | 1 | 1 |
Trypanosoma cruzi | peptidase, putative | 0.0051 | 1 | 0.5 |
Echinococcus multilocularis | nardilysin | 0.0051 | 1 | 1 |
Echinococcus granulosus | 3'partial|nardilysin | 0.0051 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | > 20000 nM | IDE Activity Assay | BINDINGDB. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.